Filter your results
- 2
- 2
- 4
- 4
- 1
- 1
- 1
- 1
- 4
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 4
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir/ritonavir in patients with COVID-19Therapeutic Drug Monitoring, 2022, ⟨10.1097/FTD.0000000000001014⟩
Journal articles
hal-03776369v1
|
||
Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.Transplant Rev (Orlando), 2011, 25 (2), pp.47-57. ⟨10.1016/j.trre.2010.06.001⟩
Journal articles
istex
inserm-00926489v1
|
|||
|
Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical ToxicologyTherapeutic Drug Monitoring, 2021, 43 (2), pp.150-200. ⟨10.1097/FTD.0000000000000871⟩
Journal articles
hal-03216543v1
|
||
|
Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil.Pharmacogenet Genomics, 2010, 20 (9), pp.537-43. ⟨10.1097/FPC.0b013e32833d8cf5⟩
Journal articles
inserm-00494526v1
|